Eli Lilly's new weight-loss pill, sold under the name Foundayo, gives consumers a second option for a non-injectable GLP-1.
The program pays active-duty, National Guard and Reserve soldiers up to $4,500 per year for a maximum of 18 semester hours.
The FDA has approved the first-ever GLP-1 pill from Wegovy maker Novo Nordisk. Novo Nordisk said the starting dose of 1.5 milligrams will be available in early January in pharmacies and via select ...
FDA proposes using a well-supported mechanistic rationale plus natural history comparators to generate substantial evidence when randomized trials are infeasible for ultra-rare populations.
In the POETYK PsA-1 and PsA-2 phase 3 trials, deucravacitinib demonstrated superior efficacy over placebo in achieving ACR20 response at week 16. The Food and Drug Administration (FDA) has approved ...
Please provide your email address to receive an email when new articles are posted on . The pathway aims to streamline approval for individualized treatments for rare and ultra-rare diseases. An ...
Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a frequent ...
The FDA made waves with its recent announcement that a single well-controlled Phase 3 study would suffice for a drug submission, replacing the previous standard of two pivotal studies. This past week, ...
Clinical data support a 5-year duration for the Nexplanon implant, with no reported pregnancies during the extended 2-year study period. The Food and Drug Administration (FDA) has extended the ...
Arden Farhi is the managing editor for CBS News' Washington bureau. He has covered several presidential campaigns and the Obama, Trump and Biden administrations. His executive producer credits include ...
South Korea's Nuclear Safety and Security Commission has received an application for standard design approval for the Innovative Small Modular Reactor from the i-SMR Technology Development Project ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results